DURECT (NASDAQ:DRRX) is set to post its quarterly earnings results after the market closes on Thursday, March 1st. Analysts expect DURECT to post earnings of ($0.05) per share for the quarter.
Shares of DURECT (NASDAQ DRRX) opened at $1.20 on Wednesday. The company has a market cap of $167.86, a price-to-earnings ratio of -8.00 and a beta of 1.79. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.57 and a current ratio of 1.67. DURECT has a one year low of $0.74 and a one year high of $2.17.
A hedge fund recently raised its stake in DURECT stock. The Manufacturers Life Insurance Company lifted its position in DURECT Co. (NASDAQ:DRRX) by 12.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,977 shares of the specialty pharmaceutical company’s stock after acquiring an additional 13,072 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of DURECT worth $189,000 at the end of the most recent reporting period. Institutional investors own 46.84% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “DURECT (DRRX) Set to Announce Earnings on Thursday” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3227011/durect-drrx-set-to-announce-earnings-on-thursday.html.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.